ǰÑÔ
·Î¼äÖÊÏËά»¯(pulmonary interstitial fibrosis)ÊÇÒÔÃÖÂþÐÔ·ÎÅÝÑ׺ͷÎÅݽṹÔÓÂÒ×îÖÕµ¼Ö·μäÖÊÏËά»¯ÎªÌØÕ÷µÄ¼²²¡£¬Æ¾Ö¤²¡ÒòÒ»Ñùƽ³£·ÖÎªÌØ·¢ÐԺͼ̷¢ÐÔÁ½Àà¡£ÃÖÂþÐԷμäÖÊÏËά»¯ÊÇÓɶàÖÖÔµ¹ÊÔÓÉÒýÆðµÄ·Î¼äÖʵÄÑ×Ö¢ÐÔ¼²²¡£¬²¡±äÖ÷ÒªÀÛ¼°·Î¼äÖÊ£¬Ò²¿ÉÀÛ¼°·ÎÅÝÉÏÆ¤Ï¸°û¼°·ÎѪ¹Ü¡£²¡ÒòÓеÄÃ÷È·£¬ÓеÄδÃ÷¡£Ã÷È·µÄ²¡ÒòÓÐÎüÈëÎÞ»ú·Û³¾ÈçʯÃÞ¡¢Ãº£»Óлú·Û³¾Èçù²Ý³¾¡¢ÃÞ³¾£»ÆøÌåÈçÑ̳¾¡¢¶þÑõ»¯ÁòµÈ£»²¡¶¾¡¢Ï¸¾ú¡¢Õæ¾ú¡¢¼ÄÉú³æÑ¬È¾£»Ò©ÎïÓ°Ïì¼°·ÅÉäÐÔËðÉË¡£Òò´Ë£¬½¨ÉèÎȹ̶ø¿É¿¿µÄ·Î¼äÖÊÏËά»¯¶¯ÎïÄ£×ÓÊÇ̽Ë÷Æä·¢²¡»úÖÆºÍ¿ª·¢ÓÐÓÃÖÎÁÆÒ©ÎïµÄÖ÷Òª°ü¹Ü¡£ÏÖÔÚ£¬·ÎÏËά»¯¶¯ÎïÄ£×ÓËù½ÓÄɵ͝ÎïÖ÷ÒªÊÇÄö³ÝÀදÎÈçСÊó¡¢´óÊó¡¢µØÊó¡¢¼ÒÍõȣ¬Ò²ÓÐÑ¡ÓýϸÅÂÔÐ͵ÄÈ®¡¢Ã¨¡¢Ñò¡¢ÖíµÈ¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó¡¢¼ÒÍÃ
¡¾ÔìÄ£»úÖÆ¡¿£º
·ÅÉäÖÎÁÆÊÇÐØ²¿Ö×ÁöµÄÖ÷ÒªÖÎÁÆÒªÁìÖ®Ò»¡£·ÅÉäÐԷμäÖÊÏËά»¯²¡±äÊÇÐØ²¿Ö×Áö·ÅÉäÖÎÁƺ󳣼ûµÄ·ÎËðÉËÐÞ¸´ÐԸı䣬¿Éµ¼ÖÂÊÜËð·Î¹¦Ð§µÄ²»¿ÉÄæÐÔËðÉË¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
Wistar´óÊó£ºÑ¡ÓÃÐÛÐÔWistar´óÊó£¬60Co-γÉäÏßÈ«ÐØÕÕÉ䣬ÕÕÉäÒ°Ãæ»ý»®·ÖΪ4.5cm×4.0cm£¬½«´óÊóÉÏÖÁÁ½Ò¸ÎÑ¡¢ÏÂÖÁÐØ¹Ç½£×´Í»µÄλÖÃÃé×¼´ËÕÕÉäÒ°£¬×ÔÐÐÉè¼Æ×°ÖÃ(10cmǦש£©ÆÁÕÏ´óÊóÆäÓಿ·Ö¡£ÕÕÉä¾àÀëΪ3m£¬¼ÁÁ¿ÂÊΪ2.7Gy/min£¬¼ÁÁ¿Îª30Gy¡£Ðγɵ䷶µÄ·ÅÉäÐԷμäÖÊÏËά»¯²¡±ä¡£
ÐÂÎ÷À¼¼ÒÍ㺽«ÊµÑé¼ÒÍÃÔÚÄ£ÖÆ¶©Î»»úÏÂ׼ȷ¶¨Î»×óÈ«·ÎµÄ¹æÄ££¬ÔÚÖ±Ïß¼ÓËÙÆ÷ÉϽÓÄÉ6mv XÏß¶Ô×óÈ«·Î¾ÙÐÐÕÕÉ䣬ÕÕÉä¼ÁÁ¿Îª25Gy, 1´Î¡£
¡¾ÔìÄ£ÌØµã¡¿£º
´óÊó·Î¼äÖÊÏËά»¯ÐγÉʱ¼ä½Ï³¤£¬Ò»Ñùƽ³£ÔÚ6¸öÔÂ×óÓÒ£¬¶àΪ¾ÖÔîÐÔ¡£ÔÚÕÕÉäºó2¸öÔÂÒÔÄÚ·ºÆðÔçÆÚ¼±ÐÔÑ×Ö¢ÆÚ»òÉøÍ¸ÆÚ£»ÕÕºó2~3¸öÔÂΪÔöÉúÆÚ£¬Ö÷ÒªÌåÏÖΪÑǼ±ÐÔϸ°ûÔöÉúÐÔת±ä£»ÕÕºó3~9¸öÔ±¬·¢ÏËά»¯£¬¸ÃÆÚÖ÷ÒªÌåÏÖΪ·ÎÅݱÚÖØ¶ÈÔöºñ£¬·ÎÅÝÇ»ÏÔ×űäСÉõÖÁÏûÊÅ£¬·ÎÅݱÚÒÔ¼°Ö§Æø¹Ü¡¢Ñª¹ÜÖÜΧµÈ·Î¼äÖʲ¿·Ö³ÉÏËάϸ°ûÓÈÆäÊÇÏËάϸ°ûÏÔ×ÅÔö¶à£¬ÇÒÔÚÕâЩ²¿Î»±¬·¢¾ÖÔîÐÔÏËά»¯£»ÕÕºó9~12¸öÔ±¬·¢ÍíÆÚ½ºÔ»¯¡£ÕÕºó2~3ÖÜ£¬·ÎÔàÍâòºÍÇÐÃæÉ¢ÔÚµã×´»òºÚµã×´³öѪ¡£ÕÕÉä4ÖÜÖ®ºó£¬ÐØÇ»»ýÉÙÁ¿»ò´óÅúµ»ÆÉ«»òºì»ÆÉ«ÒºÌ壬·ÎÔà³äѪ¡¢³öѪ¡¢Ö×ÕÍ£¬ÇÐÃæÓдó×ÚÅÝÄÑùÒºÌåÁ÷³ö£¬·ÎÌå»ýÔö´ó¡¢ÖØÁ¿ÔöÌí¡£ÕÕÉä2¸öÔÂÒÔºó£¬ ·ÎÔàµÄ¼±ÐÔÑ×Ö¢ÐÔת±äÖð½¥¼õÍË£¬3¸öÔºóÏÔ׿õÍË£¬6¸öÔºó·ÎÔà¿É¼û»Ò»ÆÉ«»ò»Ò°×É«µÄÂ̶¹´óµ½²Ï¶¹´óµÄÖÂÃÜʵ±äÇø£¬ÓÈÒÔ×ó¡¢ÓÒ·ÎÉÏÒ¶ÌåÏÖÏÔ×Å¡£¶øÎªÆÊÎö·ÅÉäÐÔ·ÎÏËά»¯µÄ²¡±ä¼ÍÂɺͱ¬·¢ÆøÖÆÌṩÐÎ̬ÒÀ¾Ý£¬Í¨¹ýÓ¦ÓÃͼÏñÆÊÎöÊÖÒÕ£¬ÓÐÑо¿¶Ô·ÅÉäÐÔ·ÎÏËά»¯ÐγÉÀú³ÌÖзμäÖÊ¡¢·ÎÅÝÇ»¡¢·ÎÄÚ»ùÖʵ¯Á¦ÏËάº¬Á¿¡¢·ÎÄÚ·Ê´óϸ°ûÊȼîÐÔ¿ÅÁ£º¬Á¿¼°·ÎÄÚ³ÉÏËάϸ°û½ºÔmRNAº¬Á¿¾ÙÐÐÁ˶¨Á¿²â¶¨¡£Ð§¹ûÏÔʾ£¬ËæÕÕÉäʱ¼äÑÓÉ죬·ÎÅݱڽ¥Ôöºñ¡¢·Î¼äÖÊËùÕ¼Ãæ»ýÔö´ó£¬·ÎÅÝÇ»¾ÙÐÐÐÔËõС¡£µ¯Á¦ÏËάÓÚÕÕºó1¸öÔÂʱ¼´¼ûÔö¶àÒ»Á¬ÖÁ6¸öÔ£¬¶øÓÚÕÕÉäºó9~12¸öÔ½üÓÚÕý³£¡£·Ê´óϸ°ûÊȼîÐÔ¿ÅÁ£º¬Á¿ÓÚÕÕÉä1¡¢2¸öÔÂÏÔ×ÅïÔÌ£¬3~9¸öÔ»ָ´½üÕý³£Ë®Æ½¡£·ÎÄÚ³ÉÏËάϸ°û½ºÔmRNAº¬Á¿ÓÚÕÕÉäºóÿ¸öʱ¼äµã¾ùÓвî±ðˮƽÔöÌí¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
Ä£×Ó»ù±¾ÉÏ¿ÉÒÔ·´Ó¦³ö·øÉäÒýÆð·Î¼äÖÊÏËά»¯µÄ²¡Àíת±ä¼ÍÂɺÍÌØµã£¬ÀûÓÚÏêϸ̽ÌÖÆä·¢²¡»úÖÆºÍÓÐÕë¶ÔÐÔµØÖ¸µ¼¸÷½×¶ÎµÄÖÎÁÆ¡£¸ÃÄ£×ÓÓÃÓÚ·øÉäÒýÆð·ÎËðÉ˵IJ¡±ä¼ÍÂÉÓëÌØµã¡¢²¡³ÌÓë·ÖÆÚ¼°Æä·ÀÖεÄÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.Ò¶Ç壬ÀîÑàÇÛ. ·ÎÏËά»¯¶¯ÎïÄ£×Ó£®ÁÙ´²·Î¿ÆÔÓÖ¾£¬2011, 16(8): 1248-1249
2.Àîΰ·å£¬ºúÓñ½à£¬Ô¬Î°·æ£¬µÈ£®Æø¹ÜÄÚµÎÈëÓëÎí»¯²©À³Ã¹ËØÖÂСÊó·ÎÏËά»¯Ä£×ӵĽÏÁ¿Ñо¿£®ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2012, 32 (2):221-225
3.À£¬Å£½¨ÕÑ£¬Jack Gauldie£¬µÈ. AdTGF-131223/225Æø¹ÜÄÚ×¢ÉäÖÆ±¸´óÊó·Î¼äÖÊÏËά»¯¶¯ÎïÄ£×ÓÖйúʵÑ鶯Îïѧ±¨£¬2006,14(1):5-7
4.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000
5.ÏÄÓ¹ÅÀö·ÎáÊØ¶û. ·ÎÏËά»¯¶¯ÎïÄ£×Ó½¨Éè¼°ÆÀ¼ÛµÄÑо¿Ï£Íû£®Ð½®´óѧѧ±¨£¬2005,28 (6):510-513
6.ξ´«É磬ÕÅ¿¡Ï飬ÕÅÑô£¬µÈ£®²©À³Ã¹ËØÐÔÑò·ÎÏËά»¯µÄʵÑéÑо¿£¨¢ò£©£ºÌÇÆ¤ÖÊÀà¼¤ËØºÍµ¤²ÎÖÎÁƵÄCTÓ벡Àí£®ÁÙ´²·ÅÉäѧÔÓÖ¾£¬2005,24(2): 166-170
7.Sriram N,Kalayarasan S,Sudhandiran G. Enhancement of antioxidant defense system by epigallocatecbin-3- gallate during bleomycin induced experimental pulmonary fibrosis. Biol Phann Bull, 2008,31 (7): 1306-1311